741 results on '"Wajant, Harald"'
Search Results
2. Systemic treatment with a selective TNFR2 agonist alters the central and peripheral immune responses and transiently improves functional outcome after experimental ischemic stroke
3. Apoptose Der programmierte Zelltod – Apoptose, Nekroptose, Ferroptose und Pyroptose
4. Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells
5. Der programmierte Zelltod – Apoptose, Nekroptose, Ferroptose und Pyroptose
6. The crosstalk between neuropilin-1 and tumor necrosis factor-α in endothelial cells.
7. Generic design principles for antibody-based tumour necrosis factor (TNF) receptor 2 (TNFR2) agonists with FcγR-independent agonism
8. Single cell analysis of human CD8+T cells reveals CD45RClow/-TNFR2+CD29lowCD8+Tregs with superior activity
9. Editorial: TNFRSF agonists: mode of action and therapeutic opportunities
10. Fn14 and TNFR2 as regulators of cytotoxic TNFR1 signaling
11. RETRACTED ARTICLE: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma
12. Analysis of FcγR-Dependent Agonism of Antibodies Specific for Receptors of the Tumor Necrosis Factor (TNF) Receptor Superfamily (TNFRSF)
13. Analysis of Ligand-Receptor Interactions Using Bioluminescent TNF Superfamily (TNFSF) Ligand Fusion Proteins
14. Activation of TNF Receptor 2 Improves Synaptic Plasticity and Enhances Amyloid-β Clearance in an Alzheimer’s Disease Mouse Model with Humanized TNF Receptor 2
15. Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation
16. Membrane lymphotoxin-α2β is a novel tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist
17. Stimulation of TNF receptor type 2 expands regulatory T cells and ameliorates established collagen-induced arthritis in mice
18. Retraction Note: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma
19. The Extracellular Domains of FasL and Fas Are Sufficient for the Formation of Supramolecular FasL-Fas Clusters of High Stability
20. NFκB Activation by Fas Is Mediated through FADD, Caspase-8, and RIP and Is Inhibited by FLIP
21. Correction: TNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAP
22. Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model
23. On-target restoration of a split T cell-engaging antibody for precision immunotherapy
24. A TNFR2-Specific TNF Fusion Protein With Improved In Vivo Activity.
25. The Type 1 Receptor (CD120a) is the High-Affinity Receptor for Soluble Tumor Necrosis Factor
26. Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors
27. Data from Anti–Tumor Necrosis Factor Therapy Inhibits Pancreatic Tumor Growth and Metastasis
28. Supplementary Figure 1 and Table 1 Legends from Anti–Tumor Necrosis Factor Therapy Inhibits Pancreatic Tumor Growth and Metastasis
29. Supplementary Table 1 from Anti–Tumor Necrosis Factor Therapy Inhibits Pancreatic Tumor Growth and Metastasis
30. Supplementary Figure 1 from Anti–Tumor Necrosis Factor Therapy Inhibits Pancreatic Tumor Growth and Metastasis
31. Basic characterization of antibodies targeting receptors of the tumor necrosis factor receptor superfamily
32. Complement 1q/Tumor Necrosis Factor-Related Proteins (CTRPs): Structure, Receptors and Signaling
33. Fas—More Than an Apoptosis Inducer
34. The FasL-Fas System in Disease and Therapy
35. TNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAP
36. The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death
37. TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity
38. Redundant and receptor-specific activities of TRADD, RIPK1 and FADD in death receptor signaling
39. Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity.
40. Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD
41. Harnessing the Expression of TNFR2 on Tregs to Prevent Agvhd
42. Targeting of the WT191–138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination
43. Genetic Engineering of Death Ligands for Improvement of Therapeutic Activity
44. Targeting fibroblast growth factor (FGF)-inducible 14 (Fn14) for tumor therapy
45. FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies
46. Recombinant Spider Silk Bioinks for Continuous Protein Release by Encapsulated Producer Cells
47. A TNF receptor 2 agonist ameliorates neuropathology and improves cognition in an Alzheimer’s disease mouse model
48. TNF Receptor Associated Factor 2 (TRAF2) Signaling in Cancer
49. The Role of FasL and Fas in Health and Disease
50. The Role of TNF in Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.